Does Medicare Advantage (Any Carrier) Cover Mounjaro?

The Federal Rule That Blocks Most Coverage

Federal law is the first wall every Medicare Advantage enrollee hits. Under Social Security Act Section 1860D-2(e)(2)(A), Part D plans are explicitly prohibited from covering drugs whose primary indication is weight loss or anorexia, regardless of how a prescriber frames the diagnosis on a claim. Eli Lilly received FDA approval for Mounjaro as a type 2 diabetes treatment in May 2022, not for obesity, so that carve-out does not apply in the way it does for semaglutide 2.4 mg (Wegovy), which received a cardiovascular-risk-reduction indication in March 2024. CMS guidance updated in 2024 clarified that only drugs with an FDA-approved cardiovascular-outcomes indication qualify for that narrow exception.

Tirzepatide does not yet hold that secondary indication. Until FDA grants one, the statutory bar applies across every carrier, including UnitedHealthcare, Humana, Aetna, BCBS affiliates, and all regional plans. No plan-level formulary decision can override the federal prohibition. A 2023 JAMA analysis confirmed that CMS exclusion criteria for weight-loss drugs affect roughly 3.4 million Medicare beneficiaries who carry an obesity diagnosis without a qualifying comorbidity covered by another statute.

The practical result: if your prescriber writes Mounjaro with obesity (ICD-10 E66.x) as the sole diagnosis, every Medicare Advantage Part D plan will reject the claim automatically.

When Type 2 Diabetes Changes the Picture

Type 2 diabetes is the one pathway that keeps coverage alive. Mounjaro is FDA-approved for glycemic control in T2D adults, so a Part D plan may place it on formulary for that indication. SURPASS-2 (N=1,879) published in the New England Journal of Medicine showed tirzepatide 15 mg reduced HbA1c by a mean 2.46 percentage points from baseline at 40 weeks, versus 1.86 percentage points for semaglutide 1 mg, a difference that was statistically significant at P<0.001. The trial also reported 12.4% mean body-weight reduction with tirzepatide 15 mg compared with 6.2% for semaglutide 1 mg, which explains why prescribers and patients alike pursue this drug for metabolic disease.

Whether your specific plan's formulary lists Mounjaro for T2D depends entirely on the carrier and plan year. Formulary placement is not uniform. Check the plan's Evidence of Coverage document or the Medicare Plan Finder tool at Medicare.gov before assuming any coverage applies. Most plans that do include it place it on Tier 4 or Tier 5 (specialty tier), with monthly cost-sharing ranging from $100 to $450 after deductible depending on the plan design.

Even when tirzepatide appears on a formulary, the plan will almost always require prior authorization. The diabetes-specific PA criteria typically include a documented HbA1c at or above 7.5%, an active T2D diagnosis, and evidence that the patient has already tried and either failed or cannot tolerate metformin at maximum tolerated dose. The American Diabetes Association's 2024 Standards of Care recommend tirzepatide as an option to reduce cardiovascular risk and body weight in patients with T2D who need additional glucose lowering beyond metformin.

Prior Authorization Criteria Across Major Carriers

Every major Medicare Advantage carrier has its own PA form, but the clinical criteria cluster around a consistent pattern. Knowing these thresholds before submission reduces the back-and-forth with the plan's pharmacy benefit manager.

Documented T2D diagnosis. The claim must carry ICD-10 E11.x. Plans cross-reference this against your Part B claims history with your primary care provider or endocrinologist. A prescription written solely against E66 (obesity) will be denied at the claims level before PA even begins.

HbA1c threshold. Most plans require a lab value of 7.5% or higher drawn within the prior 12 months, though some set the bar at 8.0%. Submit the actual lab report, not just a physician note, because pharmacy reviewers often reject verbal summaries.

Metformin trial. At least 90 days of metformin at 1 to 000 mg twice daily (or documented intolerance, such as gastrointestinal adverse effects or contraindication due to eGFR <30 mL/min/1.73m²) is required by most plans. FDA labeling for metformin contraindications and renal thresholds is published in the prescribing information.

Second-line agent trial. Many plans require a 90-day trial of an SGLT-2 inhibitor (such as empagliflozin or dapagliflozin) or a GLP-1 receptor agonist (such as dulaglutide or liraglutide) before approving tirzepatide. This is the step-therapy requirement discussed in the next section.

Prescriber specialty. Some plans give endocrinologist prescriptions more deference, but primary care providers can submit and succeed with complete documentation.

Submission checklist your prescriber needs:

• Patient's current medication list showing active metformin and any step-therapy agents
• HbA1c lab result with date
• ICD-10 E11.x diagnosis coded on the PA request
• Chart note documenting why prior agents were insufficient or not tolerated
• Requested dose and quantity (start at 2.5 mg/week per label titration schedule)

Step Therapy: Which Drugs Come First

Step therapy is a plan policy requiring a patient to try and fail (or demonstrate intolerance to) cheaper alternatives before the plan will pay for tirzepatide. The sequence varies by carrier, but a typical Medicare Advantage Part D step-therapy ladder for T2D looks like this:

Step 1: metformin (generic, low cost). Step 2: a sulfonylurea such as glipizide, or an SGLT-2 inhibitor such as empagliflozin. Step 3: a GLP-1 receptor agonist such as dulaglutide (Trulicity) or liraglutide (Victoza). Step 4: tirzepatide.

A prescriber can request a step-therapy exception if the patient has a medical reason to skip a step. Accepted reasons typically include a contraindication (for example, eGFR below the SGLT-2 threshold), a prior adverse event with a specific agent, or a compelling clinical need such as very high HbA1c requiring a more potent agent quickly. The Medicare Prescription Drug Benefit Manual Chapter 6 states that plans must grant exceptions when standard therapy is contraindicated or has not been effective.

Step-therapy exceptions require a letter of medical necessity from the prescriber. A one-sentence note does not suffice. The letter should name each skipped agent, state the specific clinical reason for skipping it, and reference supporting lab data or prior adverse-event documentation in the chart.

A 2022 JAMA Internal Medicine study examining step-therapy policies across Part D plans found that 78% of plans imposed at least two required prior-therapy steps for GLP-1 class drugs. Tirzepatide, as a newer and more expensive agent, faces even more consistent multi-step requirements.

How to Appeal a Medicare Advantage Denial

A denial is not a final answer. Medicare Advantage has a five-level appeal process, and moving through the first two levels quickly gives you the best statistical chance of reversal.

Level 1: Plan-level redetermination. You have 60 days from the denial notice to file this appeal in writing with your carrier. The plan must respond within 7 days for standard appeals and 72 hours for expedited (urgent) appeals. An expedited appeal is appropriate when the standard timeframe could seriously jeopardize your health. Submit the prescriber's letter of medical necessity, the complete PA documentation, all relevant lab work, and the denial notice itself.

Level 2: Qualified Independent Contractor (QIC) review. If the plan upholds the denial, you or your prescriber can escalate to the QIC within 60 days. MAXIMUS Federal Services currently holds the CMS contract for Medicare Part C and Part D QIC reviews. CMS publishes the current QIC contractor contact information and filing instructions at its Medicare Appeals page. MAXIMUS must resolve standard Part D appeals within 7 days and expedited ones within 72 hours.

Level 3: Office of Medicare Hearings and Appeals (OMHA). If the disputed amount meets the threshold (currently $180 for Part D in 2024), you can request a hearing before an Administrative Law Judge within 60 days of the QIC decision.

Level 4: Medicare Appeals Council. Decisions unfavorable at OMHA can go to the DAB Medicare Appeals Council.

Level 5: Federal district court. Cases meeting the jurisdictional amount threshold may be filed in federal court.

The most important practical fact: approval rates at Level 2 (QIC) are meaningfully higher than at Level 1, because an independent reviewer applies clinical criteria without the plan's financial incentive. CMS data for 2022 showed that enrollees who escalated Part D appeals to the QIC level obtained favorable decisions in approximately 44% of cases, up from roughly 18% at Level 1 redetermination.

File every appeal in writing, keep copies, and track all deadlines in a calendar. Your prescriber's office can submit on your behalf with a written authorization.

The Savings Card Problem for Medicare Beneficiaries

Eli Lilly offers a Mounjaro Savings Card through its manufacturer program. Commercially insured patients and the uninsured can use it to reduce out-of-pocket costs to as low as $25 per month in some circumstances. Medicare Advantage beneficiaries cannot use it. Full stop.

Federal anti-kickback statutes and CMS regulations prohibit using manufacturer coupons, copay cards, or assistance programs to reduce cost-sharing for drugs covered under any federal health program, including Medicare Advantage Part D. The HHS Office of Inspector General has issued multiple guidance documents confirming that accepting manufacturer cost-sharing subsidies while enrolled in a federal program violates the Anti-Kickback Statute. Using the card anyway could constitute a false claim and expose both the patient and the prescriber to liability.

This prohibition is one of the most frustrating parts of Mounjaro access for Medicare patients. At a list price of roughly $1,023 per month, cash pay is not accessible for most enrollees on fixed incomes. The alternatives are limited but real, and they are covered below.

What to Do If Coverage Is Denied and Cost Is a Barrier

When both the PA and the appeal fail, and the savings card is off the table, four paths remain.

Lilly's Insulin Value Program and patient assistance. Lilly runs a separate program called the Lilly Insulin Value Program for low-income patients and a broader Lilly Cares Foundation for patients who meet income and insurance criteria. Income limits and documentation requirements apply. Applications are processed through the Lilly Cares Foundation portal. This is distinct from the commercial savings card and does not violate federal rules for qualifying low-income patients.

Alternative GLP-1 agents on formulary. Dulaglutide (Trulicity) and liraglutide (Victoza) are older GLP-1 receptor agonists that appear on most Medicare Advantage Part D formularies at lower tiers with more accessible cost-sharing. They produce less glycemic reduction and less weight loss than tirzepatide at top doses, but they are legitimate alternatives when tirzepatide coverage fails. A 2021 meta-analysis in The Lancet Diabetes and Endocrinology (N=15 trials, 6,984 participants) ranked tirzepatide highest among GLP-1 class drugs for both HbA1c reduction and weight loss, confirming the clinical cost of switching down.

Low-Income Subsidy (Extra Help). Medicare beneficiaries who qualify for the Part D Low-Income Subsidy (LIS) pay sharply reduced cost-sharing even on specialty-tier drugs. The 2024 full LIS copay for Tier 5 specialty drugs is $11.20 per month during the initial coverage period. If you have not applied for Extra Help, contact the Social Security Administration. Eligibility is income and asset-based.

GoodRx and discount pharmacies. GoodRx and similar discount programs cannot be combined with Medicare Part D benefits, but a patient who opts to pay entirely out of pocket (bypassing Medicare for that fill) may use discount pricing. This requires a deliberate choice to not bill Medicare. The cash price with discount programs for tirzepatide can be lower than the retail list price at certain pharmacies, though it still exceeds $900 per month at most locations as of early 2025.

Monitoring and Dosing If Coverage Is Approved

Approval of tirzepatide through Medicare Advantage Part D does not end the administrative work. Most plans require a quantity limit matching the labeled titration schedule: 2.5 mg/week for 4 weeks, then 5 mg/week, with increases in 2.5 mg increments every 4 weeks to a maximum of 15 mg/week as tolerated. The FDA-approved prescribing information for Mounjaro specifies this titration schedule and lists GI adverse effects (nausea 17.6%, diarrhea 13.2%, vomiting 9.8% at 15 mg in SURPASS-2) as the primary dose-limiting factors.

Plans sometimes approve only the starting 2.5 mg dose and require a new PA for each titration step. Confirm with the plan whether dose escalations require re-authorization. If they do, build those renewals into the prescriber workflow before the current supply runs out, because a gap in therapy resets tolerability and efficacy.

HbA1c monitoring every 3 months during the first year is standard practice per ADA guidelines. The ADA 2024 Standards of Care recommend reassessing glycemic targets and medication regimens every 3 months until targets are met, then every 6 months. Submit these labs to the plan with each PA renewal to document ongoing clinical response.

Thyroid C-cell tumor risk carries an FDA boxed warning for tirzepatide. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use the drug. This is a hard contraindication, not a relative one.

Comparing Tirzepatide to Other Medicare-Covered Diabetes Drugs

Tirzepatide's dual mechanism (GIP receptor plus GLP-1 receptor agonism) produces greater HbA1c and weight reduction than any currently available single-receptor GLP-1 agent. In SURPASS-2, tirzepatide 15 mg beat semaglutide 1 mg (the highest approved T2D dose at trial time) on both endpoints. SURPASS-2 primary results published in NEJM reported a statistically significant difference in HbA1c reduction: 2.46 percentage points for tirzepatide 15 mg vs. 1.86 for semaglutide 1 mg, P<0.001, and weight loss of 12.4% vs. 6.2% respectively at 40 weeks.

Formulary alternatives with broader Medicare coverage include:

• Dulaglutide (Trulicity) 0.75 to 4.5 mg/week subcutaneous: widely covered on Tier 3 or Tier 4.
• Liraglutide (Victoza) 1.2 to 1.8 mg/day subcutaneous: Tier 3, 4 on most plans.
• Semaglutide 0.5 to 2 mg/week subcutaneous (Ozempic): Tier 4, 5 on many plans, PA required.
• Oral semaglutide (Rybelsus) 3 to 14 mg/day: occasionally on lower tiers.
• SGLT-2 inhibitors (empagliflozin, dapagliflozin): Tier 2, 3, often no PA, strong cardiovascular evidence.

If tirzepatide coverage is unavailable, a combination of an SGLT-2 inhibitor plus a GLP-1 receptor agonist may approach similar metabolic outcomes for patients who tolerate both classes. The 2023 ADA/EASD consensus report on T2D management supports combination therapy as an option when dual benefits (glycemic control plus cardiovascular protection) are needed.

Anticipating Changes: Tirzepatide for Obesity and Medicare

Tirzepatide received FDA approval for chronic weight management (as Zepbound) in November 2023 for adults with BMI 30 or higher, or BMI 27 with a weight-related comorbidity. The FDA approval announcement for tirzepatide (Zepbound) for obesity is available at FDA.gov. This is a separate product from Mounjaro but the same molecule at the same doses.

The statutory bar in Part D still applies to Zepbound. CMS cannot cover it for weight loss unless Congress amends the Social Security Act. The Treat and Reduce Obesity Act, introduced repeatedly in Congress, would remove that prohibition and allow Part D coverage of FDA-approved obesity medications. As of early 2025, it has not passed. CMS confirmed in a 2024 memorandum that the cardiovascular-outcomes exception created for semaglutide 2.4 mg (Wegovy) applies only to drugs with a specific FDA indication for reduction of cardiovascular events, not to obesity treatment broadly.

If tirzepatide receives an FDA cardiovascular-outcomes indication in a future trial, the coverage picture would change immediately and plans would be permitted (though not required) to add it to formularies under the cardiovascular exception. The SURMOUNT-MMO trial is currently evaluating tirzepatide on major adverse cardiovascular events in patients with obesity. Results are expected in 2025 or 2026.